Tags

Type your tag names separated by a space and hit enter

Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
Int J Infect Dis. 2019 Apr; 81:221-224.IJ

Abstract

Post-kala-azar dermal leishmaniasis (PKDL) is a neglected tropical disease characterized by a dermatosis which often appears after successful treatment of visceral leishmaniasis caused by Leishmania donovani. PKDL treatment options are few and have severe limitations. In East-Africa, the standard treatment of PKDL is with daily painful potentially toxic sodium stibogluconate injections, administered for a prolonged duration of 30-60 days. In the Indian subcontinent, PKDL is mainly treated with miltefosine, a safer orally administered drug. However, in East-Africa, there is very limited experience in the use of miltefosine for treatment of severe PKDL, with only one published case report. Here we report a severe PKDL case in an Ethiopian HIV patient successfully treated with oral miltefosine (100mg/day for 28 days). Miltefosine was efficacious, safe and well tolerated, suggesting that it can play an important role in the treatment of severe PKDL also in East-African patients. Further research is warranted.

Authors+Show Affiliations

Médecins Sans Frontières - Holland, Yeke Subcity, Woreda 7, Kebele 11/12, House #605, Balderas (in front of Levi Building), P.O BOX 34357, Addis Ababa, Ethiopia. Electronic address: abongomera@yahoo.com.Médecins Sans Frontières - Holland, Yeke Subcity, Woreda 7, Kebele 11/12, House #605, Balderas (in front of Levi Building), P.O BOX 34357, Addis Ababa, Ethiopia; Institute of Tropical Medicine, Nationalestraat 115, B-2000, Antwerp, Belgium. Electronic address: tbattaglioli@itg.be.Médecins Sans Frontières - Holland, Yeke Subcity, Woreda 7, Kebele 11/12, House #605, Balderas (in front of Levi Building), P.O BOX 34357, Addis Ababa, Ethiopia. Electronic address: cherinetadera@yahoo.com.Médecins Sans Frontières - Holland, Naritaweg 10, 1043 BX Amsterdam, The Netherlands. Electronic address: koert.ritmeijer@amsterdam.msf.org.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

30790722

Citation

Abongomera, Charles, et al. "Severe Post-kala-azar Dermal Leishmaniasis Successfully Treated With Miltefosine in an Ethiopian HIV Patient." International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, vol. 81, 2019, pp. 221-224.
Abongomera C, Battaglioli T, Adera C, et al. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient. Int J Infect Dis. 2019;81:221-224.
Abongomera, C., Battaglioli, T., Adera, C., & Ritmeijer, K. (2019). Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 81, 221-224. https://doi.org/10.1016/j.ijid.2019.02.012
Abongomera C, et al. Severe Post-kala-azar Dermal Leishmaniasis Successfully Treated With Miltefosine in an Ethiopian HIV Patient. Int J Infect Dis. 2019;81:221-224. PubMed PMID: 30790722.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient. AU - Abongomera,Charles, AU - Battaglioli,Tullia, AU - Adera,Cherinet, AU - Ritmeijer,Koert, Y1 - 2019/02/18/ PY - 2019/02/01/received PY - 2019/02/08/revised PY - 2019/02/13/accepted PY - 2019/2/23/pubmed PY - 2019/8/28/medline PY - 2019/2/22/entrez KW - East-Africa KW - Ethiopia KW - HIV KW - Miltefosine KW - Post-kala-azar dermal leishmaniasis KW - Treatment SP - 221 EP - 224 JF - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JO - Int J Infect Dis VL - 81 N2 - Post-kala-azar dermal leishmaniasis (PKDL) is a neglected tropical disease characterized by a dermatosis which often appears after successful treatment of visceral leishmaniasis caused by Leishmania donovani. PKDL treatment options are few and have severe limitations. In East-Africa, the standard treatment of PKDL is with daily painful potentially toxic sodium stibogluconate injections, administered for a prolonged duration of 30-60 days. In the Indian subcontinent, PKDL is mainly treated with miltefosine, a safer orally administered drug. However, in East-Africa, there is very limited experience in the use of miltefosine for treatment of severe PKDL, with only one published case report. Here we report a severe PKDL case in an Ethiopian HIV patient successfully treated with oral miltefosine (100mg/day for 28 days). Miltefosine was efficacious, safe and well tolerated, suggesting that it can play an important role in the treatment of severe PKDL also in East-African patients. Further research is warranted. SN - 1878-3511 UR - https://www.unboundmedicine.com/medline/citation/30790722/Severe_post_kala_azar_dermal_leishmaniasis_successfully_treated_with_miltefosine_in_an_Ethiopian_HIV_patient_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1201-9712(19)30076-1 DB - PRIME DP - Unbound Medicine ER -